← Oncology Approval Tracker

FDA DECISION ·

Tecentriq

atezolizumab · Genentech

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment for adults with metastatic non-small cell lung cancer, high PD-L1 expression by an FDA-approved test (at least 50% of tumor cells or immune-cell staining over at least 10% of tumor area), and no EGFR or ALK aberrations.

LAMPGEN ANALYSIS

Why it matters

Made single-agent immunotherapy available first line for an assay-defined high PD-L1 population.

What research teams should watch

Store the assay and scoring method and document EGFR and ALK results before treatment selection.

PRIMARY RECORDS

Sources